Χώρα: Αυστραλία
Γλώσσα: Αγγλικά
Πηγή: Department of Health (Therapeutic Goods Administration)
Lamotrigine
Aspen Pharma Pty Ltd
Medicine Registered
LAMOTRIGINE ASPEN (lamotrigine) dispersible tablets – Consumer Medicine Information Page 1 of 5 LAMOTRIGINE ASPEN DISPERSIBLE TABLETS _lamotrigine _ CONSUMER MEDICINE INFORMATION (CMI) There are reports of severe, potentially life-threatening rashes associated with lamotrigine treatment, particularly in children. Lamotrigine Aspen should be discontinued at the first sign of rash unless the rash is clearly not drug related. WHAT IS IN THIS LEAFLET This leaflet answers some common questions about LAMOTRIGINE ASPEN. It does not contain all of the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have benefits and risks. Your doctor has weighed the risks of you taking LAMOTRIGINE ASPEN tablets against the benefits they expect it will have for you. IF YOU HAVE ANY CONCERNS ABOUT TAKING THIS MEDICINE, TALK TO YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET WITH YOUR MEDICINE. You may need to read it again. WHAT LAMOTRIGINE ASPEN IS USED FOR Lamotrigine (the active ingredient in LAMOTRIGINE ASPEN tablets) belongs to a group of medicines called “anti-epileptic drugs”. LAMOTRIGINE ASPEN tablets are used to treat epilepsy, including partial or generalised seizures, in adults and children. In general, it is initially used [in addition to other medicines] for treatment of this condition. An epileptic seizure, fit or turn results when abnormal electrical impulses occur in nerve cells in the brain. These abnormal electrical impulses are believed to be due to altered levels of some chemicals in the brain. It is thought to work by changing the levels of some of the chemicals associated with seizures. ASK YOUR DOCTOR IF YOU HAVE ANY QUESTIONS ABOUT WHY LAMOTRIGINE ASP Διαβάστε το πλήρες έγγραφο
LAMOTRIGINE ASPEN (lamotrigine) – Product Information Page 1 of 21 PRODUCT INFORMATION LAMOTRIGINE ASPEN 25, 50, 100, 200 _lamotrigine dispersible tablets 25/50/100/200 mg _ Severe, potentially life-threatening rashes have been reported in association with the use of lamotrigine, particularly in children. Accordingly, lamotrigine should be discontinued at the first sign of rash unless the rash is clearly not drug related (see DOSAGE AND ADMINISTRATION). NAME OF THE MEDICINE Lamotrigine Chemical name: 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine. CAS: 84057-84-1. DESCRIPTION Lamotrigine is a substituted asymmetric triazine. The pKa of lamotrigine at 25 ⁰C is 5.7. It is a white to pale cream coloured powder. It is slightly soluble in ethanol and chloroform and very slightly soluble in water. The active ingredient in LAMOTRIGINE ASPEN tablets is lamotrigine. The tablets also contain the inactive ingredients crospovidone, povidone, mannitol, cellulose-microcrystalline, silica- colloidal anhydrous, aspartame, croscarmellose sodium, magnesium stearate and trusil blackcurrant S4468 (PI). PHARMACOLOGY The precise mechanism of the anticonvulsant action of lamotrigine is not certain. The results of neurochemical and electrophysiological studies with various _in vitro_ and _in vivo_ preparations indicate that lamotrigine can inhibit voltage gated sodium channels and reduce the release of glutamate, an excitatory amino acid implicated in the pathophysiology of epilepsy. It is possible that these effects underlie inhibition of the sustained repetitive firing of action potentials characteristic of neurons in epileptic foci, thereby limiting the spread of seizures. In tests designed to evaluate the CNS effects of drugs, the results obtained using d Διαβάστε το πλήρες έγγραφο